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PEMBETULAN MUTASI GLUCOSE-6-PHOSPHATE DEHYDROGENASE 
(G6PD) VIANGCHAN DALAM MONOSIT DENGAN MENGGUNAKAN 
CRISPR/CAS9 
 
ABSTRAK 
 Kekurangan G6PD adalah antara penyakit enzim yang paling biasa dihidapi 
manusia dengan kira-kira 400 juta orang yang terjejas olehnya di seluruh dunia. Dua 
ratus tujuh belas jenis mutasi telah ditemui setakat ini dan ada sebilangan jenis mutasi 
ini boleh menyebabkan maut. Kekurangan G6PD juga dikaitkan dengan pelbagai 
jenis kanser, tumor dan penyakit metabolik. Kajian ini bertujuan untuk membaiki 
kekurangan G6PD dengan menggunakan sistem CRISPR / Cas9. Kajian ini 
menggunakan G6PD Viangchan, sejenis mutasi yang lazim dijumpai dalam kalangan 
etnik Melayu Malaysia. G6PD Viangchan telah diklon ke dalam plasmid 
pengekspresan pET26b (+) dan  diekpreskan di dalam sistem BL21 (DE3). Protein 
rekombinan G6PD Viangchan yang terhasil telah disahkan dengan membandingkan 
aktiviti enzimnya dengan G6PD wildtype. Keputusan menunjukkan protein G6PD 
Viangchan telah berjaya dihasilkan dengan menggunakan sistem ekspresi 
heterologous. Expresi enzim telah dikurangkan sehingga 67% berbanding G6PD 
wildtype. Seterusnya, G6PD Viangchan telah diklonkan ke dalam plasmid 
pengekspresan lentiviral, pLJM-eGFP, untuk menghasilkan zarah lentiviral. Virus 
ini digunakan untuk mentransdusi sel THP-1 untuk menghasilkan sel THP-1 yang 
mengekpres protien G6PD Viangchan secara stabil. Enzim yang dihasilkan oleh sel 
tersebut telah disahkan dengan menggunakan ujian aktiviti enzim. Keputusan 
menunjukkan sel THP-1/G6PD Viangchan menghasilkan tahap enzim G6PD yang 
lebih rendah (lebih kurang 50 %) berbanding dengan sel THP-1 yang tidak 
 xviii 
 
ditransduksi. Akhirnya, kekurangan tersebut telah diperbaiki dengan menggunakan 
sistem suntingan gen CRISPR / Cas9. GuideRNA (gRNA) yang mengapit kawasan 
mutasi telah dihasilkan menggunakan kaedah PCR dan telah ditranskripkan kepada 
RNA. Sel THP-1/G6PD Viangchan telah ditransfek dengan menggunakan gRNA, 
DNA Cas9 dan DNA donor dengan menggunakan Lipofectamine 3000. Walaupun 
begitu, suntingan gen berasaskan CRISPR hanya berupaya meningkatkan sebanyak 
8.8 % enzim G6PD berbanding sel kawalan yang tidak ditransdusi. Pengoptimuman 
untuk suntingan gen berasaskan CRISPR amat diperlukan untuk  pembaikan gen 
yang lebih tinggi. Meskipun begitu, kajian ini membentuk satu struktur asas dalam 
menyediakan pendekatan baru untuk terapi kekurangan enzim G6PD dengan 
menggunakan pendekatan molekular. 
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CORRECTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE 
(G6PD) VIANGCHAN MUTATION IN MONOCYTES USING 
CRISPR/CAS9 
 
ABSTRACT 
G6PD deficiency is one of the most common enzymopathy in human with 
approximately 400 million people affected worldwide. Two hundred seventeen types 
of mutations have been described so far with some mutations are life threating. G6PD 
deficiency has also been linked to various types of cancers, tumours and metabolic 
diseases. This study aimed to correct G6PD deficiency by using CRISPR/Cas9 
system. In this study, G6PD Viangchan as used; a type of mutation which is common 
in Malaysian Malays. G6PD Viangchan has cloned into pET26b (+) expression 
plasmid and expressed in BL21 (DE3) system. The recombinant G6PD Viangchan 
protein was verified by comparing its enzyme activity with G6PD wild type. Results 
showed a successful production of G6PD Viangchan protein by using heterologous 
expression system. The enzyme expression was reduced up to 67 % compared to 
G6PD WT. Subsequently, G6PD Viangchan was cloned into a lentiviral expression 
plasmid, pLJM-eGFP, to produce lentiviral particles. These particles were used to 
transduce THP-1 cell line, in order to generate stable G6PD Viangchan-expressing 
cells. The stable cell line was verified by using enzyme activity assay. THP-1/G6PD 
Viangchan cells produced a lower amount of G6PD enzyme (approximately 50 %) 
compared to untransduced THP-1 cells. Consecutively, the deficient was corrected 
by using CRISPR/Cas9 genome editing system. Guide RNAs flanking the mutation 
site were produced by using PCR approach and in vitro transcribed into RNA. G6PD 
deficient THP-1 cells were transfected with gRNA, Cas9 DNA and donor DNA by 
 xx 
 
using Lipofectamine 3000. However, CRISPR-based gene editing only managed to 
increase approximately 8.8 % of G6PD enzyme compared to the untransfected 
control cells. Optimisations for CRISPR-based gene editing are much needed to 
obtain a higher percentage of gene correction. Nevertheless, this study forms a 
fundamental structure in providing a new opportunity in therapy for G6PD deficiency 
by using molecular approach. 
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1.0 GENERAL INTRODUCTION 
Red blood cells (RBC) require a source of energy to efficiently perform its function 
and for its survival in the circulation for approximately 120 days (Brouillard, 1974). 
Glucose is the normal energy source of the red blood cell which is metabolised by the 
RBC along two major routes, the glycolytic pathway and the pentose phosphate 
pathway (PPP) (Xiao et al., 2018). In PPP pathway, glucose-6-phosphate is oxidized 
to 6-phosphoglucono-δ-lactone. The reaction is catalysed by glucose-6-phosphate 
dehydrogenase (G6PD) enzyme and coupled with NADP+ reduction into NADPH 
(Patra and Hay, 2014). NADPH is used in reducing GSSG to GSH. Normal cells can 
defend themselves against oxidative stress reducing GSSG to GSH. However, G6PD 
deficient red cells are unable to reduce NADH to NADPH at the normal rate, hence 
lowering the conversion rate of hydrogen peroxide or the mixed disulphides into 
haemoglobin and glutathione (GSH). This metabolic even lead to red cell damage and 
eventually destruction or haemolysis as discussed in Figure 1.1 (Beutler, 2018). 
G6PD deficiency is an X-linked genetic disease which can be inherited. 
Individuals with G6PD deficiency often appears asymptomatic unless triggered by 
infection, drugs, mothballs and fava beans (Cappellini and Fiorelli, 2008). These 
triggers cause RBC to break down prematurely and results in early destruction of red 
blood cells is called hemolysis (Shalev et al., 1985). Figure 1.2 shows a sketch by Jorge 
Muniz was published on Twitter in the 7th Sep 2015 on the condition of G6PD 
deficiency. Sketch was upload to create more awareness about the disease among the 
common people. It is shown that the red blood cells undergo series of haemolysis after 
exposed to oxidative drugs such as aspirin, sulphonamides, nitrofurantoin, dapsone, 
primaquine and quinidine. Favism and infection can also trigger haemolysis anaemia 
in the patient.  
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Figure 1.1: Hydrogen peroxide is being generated and detoxified in the erythrocytes. 
In G6PD patients, insufficient amount of NADPH results in accumulation of GSSH 
which leads to haemoglobin denaturation and decrease RBC survival. GR-glutathione 
reductase; GSH Px-glutathione peroxide; GSSH-glutathione disulphide (oxidized 
glutathione); Sup Dismut- superoxide dismutase (Williams and Lichtman, 2006). 
 
 
 
Figure 1.2: Hemolysis in G6PD deficient cells is caused by oxidative drugs, favism 
and infection. The sketch also illustrates the formation of Heinz body and bite cells 
due to drug induced hemolysis in G6PD deficient cells (Muniz, 2015). 
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1.1 Background of problem 
G6PD gene is a housekeeping gene present in all cells. G6PD enzyme, a product of 
G6PD gene is involved in the first enzymatic reaction in pentose phosphate pathway 
(PPP) by converting glucose-6-phosphate to 6-phosphogluconolactone and 
simultaneously reduces NADP+ to NADPH (Kuby 1962). G6PD is the sole producer 
of NADPH (Filosa et al., 2003) and plays a significant role to protect cells against 
oxidative stress and to maintain cells in a reduced state. G6DP deficiency is the most 
common genetic enzyme deficiencies with approximately 400 million people living 
with it (Cappellini and Fiorelli, 2008). G6DP deficiency is X-linked genetic disorder 
affecting men. However, females can also be affected.  
G6PD Viangchan variant is classified into G6PD Class II according to World 
Health Organisation (WHO). The world health organization classified G6PD 
deficiency variants into five different classes as shown in Table 1.1. G6PD deficiency 
falls under severe deficiency with less than 10 % of G6PD normal activity and can 
cause clinical implication such as intermittent haemolysis. G6PD deficiency varies 
according to its classes. Individuals with G6PD deficiency often suffer from a number 
of diseases such as neonatal jaundice, favism, drug or infection related haemolytic and 
chronic non-spherocytic haemolytic anaemia.  
G6PD deficiency also has been linked to hepatitis A and E (Hu et al., 2014, 
Gotsman and Muszkat, 2001, Monga et al., 2003)  and dengue infection (Al-alimi et 
al., 2014, Chao et al., 2008, Tanphaichitr et al., 2002). Additionally, G6PD deficiency 
is also often associated with high oxidative stress in the cell. High oxidative stress is 
also linked to cancer. G6PD is found to be activated in many cancers and tumors 
including breast cancer (Bokun et al., 1986, Pu et al., 2015), cervical cancer (Duţu et 
al., 1979, Hu et al., 2015), prostate cancer (Zampella et al., 1982, Tsouko et al., 2014), 
 4 
 
endometrial cancer (Hughes, 1976), lung tumors (Pisano et al., 1991), renal cancer 
(Zhang et al., 2017b), ovarian cancer (Yi et al., 2015), bladder cancer (Wang et al., 
2015) and gastric cancer (Wang et al., 2012). 
 
Table 1.1: WHO classification for G6PD deficient variants 
Types of class Sereverity  Percentage of activty Clinical 
complication 
Class I Severe deficiency <10 % activity chronic 
(nonspherocytic) 
hemolytic anemia 
Class II Severe deficiency <10 % activity intermittent 
hemolysis 
Class III Mild deficiency 10-60 % activity hemolysis with 
stressors only 
Class IV Non-deficient variant 60-150 % of enzyme 
activity 
no clinical 
sequelae 
Class V Increased enzyme 
activity 
>150 % of normal 
activity 
no clinical 
sequelae 
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1.2 Problem statements  
G6PD deficiency can be classified into different variants according to the position of 
this mutation. Viangchan type variant has a mutation that lies on the position 871 on 
its nucleotide. It is one of the common variant is Malaysian Malay population which 
comprises of 32.7% followed by Mahidol and Mediterranean variants (Ainoon et al., 
2002).  Henceforth, the study was designed by targeting the Viangchan type variant. 
Nevertheless, the prevalence of G6PD deficiency in Malaysia is 3.1 % among males 
and was shown to be commonest among Malays and Malaysian Chinese and less 
common among the Indians (Singh, 1986, Hon et al., 1989).  
There are no defined treatments for G6PD deficiency. Normally, patients often live 
by avoiding the G6PD triggers for the entire life. The treatment work more on 
managing the haemolysis rather than a curing the disease. Patients are often managed 
by controlling occurrence of haemolytic anaemia that is caused by the triggers. In some 
severe cases for instance in chronic non-spherocytic haemolytic anaemia (CNSHA), 
patients might need blood transfusion for their entire life.  
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1.3 Objectives of the study 
General objective: 
The main objective of the study is to correct G6PD deficiency in THP-1 cell line by 
using ribonucleic CRISPR-Cas9 system. 
Specific objective:  
1) To produce full length functional normal and mutated (Viangchan) G6PD protein. 
Through this study, protein production and enzyme activity of both wild type and 
disease protein were studied and compared. 
2) To generate viral particles by using lentiviral third generation system.  Third 
generation lentiviral system was chosen over the second generation because it 
produces safer virus particles compared to previous lentiviral system.  
3) To establish stable G6PD deficient THP-1 cell line by using the produced viral 
particles. The disease model was expected to produce lower expression of G6PD 
protein.  
4) To correct the deficient by using ribonucleic CRISPR/Cas9 system. The correction 
utilized homology directed repair by using donor template (ssODN) by fixing the 
single site mutation.  
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2.0 LITERATURE REVIEWS 
 
2.1 Red blood cells (RBC)  
2.1.1 Introduction 
The term erythropoiesis was derived from the Greek terms “erythros” (red) and 
“poiein” (making) and describes the process of the production of red blood cells (RBC) 
(Colman, 2009). Erythron which include both the progenitor and adult red cells is the 
term used to emphasise the idea that they function as an organ. RBCs are highly 
differentiated cells that have no nuclei or cytoplasmic organelles. They do not contain 
ribosomes; they cannot synthesise protein to replace molecules such as enzymes, 
structural proteins which become denatured. Normal RBCs are in  biconcaves disc 
with an average diameter of 7.2 µm and thick of 2.0 µm as shown in Figure 2.1 
(Wickramasinghe & Erber, 2011). RBC have a limited life span of 110-120 days, at 
the end of which they are ingested and degraded by the macrophages of the marrow, 
spleen, liver and other organs (Franco, 2012).  
2.1.2 Production of red blood cells 
Production of RBC or erythropoiesis is a tightly regulated process by which 
hematopoietic stem cells differentiate into erythroid progenitors and then mature into 
RBC as shown in Figure 2.2. Erythropoietin (EPO) which is produced in kidneys is 
the principal hormone regulating erythropoiesis (Jacobson et al., 1957). RBC are 
produced from multipotent haemopoietic cells (Wickramasinghe, 1975) which  reside 
in the bone marrow and are stimulated by variety of hormones or cytokines. The 
earliest characterised progenitor committed to the erythroid lineage is the burst 
forming unit-erythroid (BFU-E). This progenitor requires multiple factors for 
proliferation and prevention of apoptosis to differentiate into a late progenitor, colony 
forming unit-erythroid (CFU-E) (Elliott et al., 2008). Beyond the CFU-E stage, 
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erythroid progenitors are largely regulated by EPO to form erythroblasts, the precursor 
cells (Lodish et al., 2010). These cells develop from there, proliferate and differentiate 
into reticulocytes which will be released into the circulation for development into 
mature RBC.  
2.1.3 Function of red blood cells (RBC) 
The prime function of the RBC is to combine with oxygen in the lungs and to transport 
and release this oxygen for utilisation of the tissues. The red cells also combine with 
carbon dioxide (CO2) produced in tissues and release this in the lungs. The function of 
oxygen transport resides in the haemoglobin which is made up of two α (alpha) and 
two β (beta) subunits as shown in Figure 2.3. To achieve an optimal performance as 
an oxygen transporter the red cells require a healthy RBC membrane and healthy 
enzyme systems provide energy and protect against oxidant damage. The RBC 
membrane is composed of a lipid bilayer and is bound to a sub-membranous 
cytoskeletal network which is responsible for maintaining the biconcave shape of a 
normal RBC (Peng et al., 2013).  
The membrane contains adenosine triphosphate (ATP)-dependent pumps as 
shown in Figure 2.4 that counteracting a continuous passive diffusion of ions across 
the membrane in the opposite direction. In the resting state 90 % of glucose is 
catabolised anaerobically through the Embden-Meyerhof pathway, which also serves 
to generate nicotinamide adenine dinucleotide (NAD+) in its reduced form NADH, 
required as cofactor for cytochrome b5 reductase for the conversion of 
methaemoglobin to haemoglobin. 
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Figure 2.1: Top view and side view of a red blood cell with average diameter of 7.2 µm and average thick of 2.0 µm. It is composed of 
lipid bilayer and bounded to sub-membranous cytoskeletal network (Marieb and Hoehn, 2007). 
 
 
 
 
 
 
Figure 2.2:  Development of RBC from hemocytoblast. Three phases are involved, production of ribosomes, synthesis of haemoglobin 
and ejection of nucleus and organelles (Marieb and Hoehn, 2007).  
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Figure 2.3: Structure of haemoglobin that consist of α and β chains. Each chain consists 
of a heme group that holds an iron atom respectively (Johnson et al., 1995). 
 
 
 
 
 
Figure 2.4: The sodium-potassium exchange pump (Staff, 2014). The membrane 
consists of potassium/sodium ions pump which uses ATP as the source of energy. The 
top part shows the extracellular fluid and the inner part shows the cytoplasm.  
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2.2 RBC disorders 
Hoffbrand in his book entitled “Postgraduate Haematology” has categorised RBC 
disorders into numerous subgroups and G6PD deficiency falls under section : 
Disorders of red blood metabolism (Hoffbrand et al., 2016). Only disorders of red 
blood metabolism will be discussed in subsequent section. 
2.2.1 Disorders of red blood metabolism 
RBC play an important role to carry haemoglobin around the blood circulation in 
optimal concentration and in a functional state to allow an efficient gas exchange in 
the lungs and tissue capillaries (Beutler and Waalen, 2006). In order to achieve this; 
the red blood cells need a constant supply of energy in the form of ATP and a source 
of reducing power (Betz et al., 2009). The energy is derived from anaerobic glycolysis 
and PPP. ATP is required to maintain the membrane in its deformable state, with 
asymmetric lipid layers, and to regulate ion and water exchange (Nagy et al., 1997). 
G6PD enzyme catalyses the first step of PPP which reduces nicotine adenine 
dinucleotide phosphate (NADPH)  pathway too (Kruger and von Schaewen, 2003).  
NADPH drives the glutathione cycle, glutathione (GSH) being the major reducing 
agent within the red cell (Schafer and Buettner, 2001). Reduction of any enzyme in the 
mature red cells means none of the enzymes in the metabolic pathways can be replaced 
during the red cell lifespan. Enzyme activities will decline until a new normal red cell 
is produced.  
G6PD enzyme by far is one of the most important enzymes in PPP and its 
deficiency results in accumulation of reactive oxygen species in cell which will 
eventually destroy the RBC. G6PD deficiency will be further explained in next section 
2.3. 
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2.3 G6PD DEFICIENCY 
2.3.1 History  
In the year 1926, a group of individuals developed haemolytic anaemia while being 
treated for  malaria with 6-methoxy-8-aminoquinoline drugs (Beutler et al., 1954). The 
questions arise whether the drug doesn’t compatible to the malaria patient or did the 
patients’ RBC differ in some way. To solve this, Sterling and Gray was first to use 
51Cr method to label the RBC and found out that sensitivity of the haemolytic effect of 
primaquine was due to an intrinsic defect of the RBC (Sterling and Gray, 1950). Few 
years later, Carson studied the reduction of glutathione by hemolysates. He discovered 
that hemolysates from primaquine-sensitive men could not utilise glucose-6-
phophatase to reduce glutathione, concluding that primary defect was in glucose-6-P-
ulilizing enzyme, G6PD (Carson et al., 1956). It was later found that besides 
primaquine, other drugs including sulphanilamide, acetanilide and some sulfones also 
trigger haemolysis (Beutler, 2008). Till then, G6PD deficient is still not discovered 
and drug administration was performed very carefully according to individual’s drug 
ingestion history. 
 G6PD deficiency was first found in African-American subjects and was 
restricted to a single ethnic group only. Due to that reason, it was categorised as genetic 
based disorder  (Browne, 1957). The same group also discovered that G6PD deficiency 
was an X-linked disorder and that affects primarily the RBC, older cells being more 
severely affected than newly formed. In the year 1961, it become apparent that the 
disorder did not limited exclusively among people of Africa but also Southern Europe 
and the Middle East. Besides, Marks and Gross shown that G6PD deficiency in 
Mediterranean peoples were much more severe than among African Americans. In the 
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year 1967 (WHO, 1967), World Health Organisation (WHO) published standard 
method to measure G6PD enzyme and later in 1971 they sponsored a study.  
 G6PD deficiency classifications according to its enzyme activity was 
published from the study (Yoshida et al., 1971). By the year 1988, more than 370 
variants  were described (Beutler and Yoshida, 1988). Since some types of variant 
found to be redundant, a recent review has re-categorised the different types of variants 
into 217 types mutation (Gómez-Manzo et al., 2016b, Gómez-Manzo et al., 2017). 
Although the disorder was discovered in early days, the real mechanism of haemolysis 
was fully discovered after 30 years. The discovery has opened a lot of door to study 
biochemical pathways. 
2.3.2 Genetics and Inheritance 
G6PD gene is located in the distal long arms of the X chromosome at the Xq28 locus 
(Figure 2.5). The gene contains 13 exons and 12 introns which are over 18.5 kb in 
length (Martini et al., 1986). G6PD enzymes have 515 amino acids, which translated 
into 59, 256 Da proteins. G6PD mRNA encodes two isoforms, G6PDH isoform (a) 
(545 amino acids) and isoform (b) (515 amino acids). The 545 amino acid isoform (a) 
protein is inactive but post-translational processing results in a 515 amino acid which 
is the functional protein containing an acetylated alanine residue at the N-terminus.  
 Biologically active G6PDH is functional as either a homodimer or a 
homotetramer and both forms co-exist in equal proportions at neutral pH as shown in 
Figure 2.6. G6PD deficiency is an X-linked recessive disorder. Males usually manifest 
the abnormality and females are carriers. For this reason, the defect is fully expressed 
in affected males and is never transmitted from father to son, but only from mother to 
son. The main cause of the deficiency is single site mutation. Although more than 400 
types of mutation has been described so far, a precise molecular characterisation shows 
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mainly 140 missense mutation leading to amino-acid substitution (Beutler et al., 1996, 
Mason and Vulliamy, 2003).  Despite that, a recent extensive review was published, 
recognizing 217 mutations in the G6PD gene that are responsible for the severity of 
the clinical symptoms (Gómez-Manzo et al., 2016b, Gómez-Manzo et al., 2017). 
Figure 2.7 shows few types of mutations that have been mapped against the G6PD 
exons. 
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Figure 2.5: Position of G6PD gene in X chromosome. G6PD gene is located at lower 
arm q at position 28 (Cappellini and Fiorelli, 2008). 
 
 
 
 
Figure 2.6: Dimer form of G6PD gene structure showing active site for G6P and 
NADP+ ligand (Hoffbrand et al., 2016). 
 
 
Figure 2.7: G6PD gene map showing mutation sites. Numbers in boxes refer to the 
location of G6PD exons (courtesy of Tom Vulliamy, Hammersmith Campus, 
Imperial College, London) (Hoffbrand et al., 2016).   
 
Legends: Numbered boxes refer to the location of G6PD exons: yellow circles, class 
I and II variants; yellow ellipses, class IV variants; red circles, polymorphic 
variants; green circles and squares, class I variants caused by amino acid 
substitutions and small in-frame deletions, respectively. 
 16 
 
2.3.3 Pathophysiology 
G6PD is expressed in all cells and is responsible for the first enzymatic reaction of 
PPP in which glucose-6-phosphate is oxidised to 6-phosphogluconolactone with 
simultaneous production of NADPH as shown in Figure 2.8. The G6PD / NADPH 
pathway is the sole source of reduced glutathione in RBC (Verrelli et al., 2002, Filosa 
et al., 2003). The production of NADPH is required for a variety of reductive 
biosynthetic reactions. One and foremost is for production of reduced form of GSH 
which plays an important role on detoxification of hydrogen peroxide (H2O2) (Gaetani 
et al., 1996, Scott et al., 1993, Kirkman et al., 1987). H2O2 is toxic by-product of 
cellular metabolism in aerobic organism which is also known as reactive oxygen 
species (McCord and Fridovich, 1969).  
NADPH functions to defend against the oxidizing effects of H2O2 (Figure 2.9). 
The NADPH produced in the PPP, and the antioxidant GSH, are both necessary for 
the continual removal of ROS from the RBC. When a patient present with G6PD 
deficiency, he or she is usually asymptomatic unless triggered by oxidant agent known 
as triggers. The oxidant will creates more free ROS in the red cells. Glutathione 
predominantly will be active in the cells but without G6PD, they will be failed to act 
further and stay in their oxidised form. Hence, the free radical forms Heinz bodies and 
stick to the red cell membrane (Mannoji et al., 1985). Cell membrane damaged by the 
Heinz bodies and ROS become distorted and the cell is likely to undergo lysis. 
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2.3.4 Prevalence and Geographic Distribution 
The condition affects up to 1 % of the world population but is considerably higher with 
gene frequencies from 5-25 % in tropical Africa, Middle East, tropical and subtropical 
Asia, some areas of the Mediterranean and Papua New Guinea as shown in Figure 
2.10.  The prevalence of G6PD deficiency was found to be higher in malaria endemic 
countries (Howes et al., 2012). The first identified variant is G6PD A- 
(G202A/A376G) (Comfort, 2009). The variant is rare for having double point mutation 
and very common in the sub-Saharan African population. G6PD Mediterranean was 
predominant in West Asia (from Saudi Arabia and Turkey to India) (Howes et al., 
2013). Howes reported  multiple variants co-occurring with no single variant being 
predominant in Southeast Asia (Howes et al., 2013). However the previous report 
shows Mahidol variant (G487A) is common especially across Myanmar, Thailand and 
Indonesia (Phompradit et al., 2011). 
The prevalence of G6PD deficiency in Malaysia is 3.1 % among males and was 
shown to be commonest among Malay ethnics and Malaysian Chinese and less 
common among the Indians. Another small study comprises 87 people shows similar 
result but a higher prevalence 4.59 % (Sulaiman et al., 2013). The  most common type 
of variant in Malay ethnic is G6PD Viangchan (37.2 %), followed by G6PD  
Mediterranean (26.7 %) and G6PD Mahidol (15.1 %) (Ainoon et al., 2003, Yusoff et 
al., 2004). G6PD Viangchan variant carries point mutation at position 871 (G>A). 
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2.3.5 Viangchan mutation 
G6PD Viangchan gets its name from the name of the capital city of Laos which is also 
known as Vientiane. In the year 1988, G6PD Viangchan was first characterised 
biochemically from a Laotian immigrant G6PD-deficient patient who lives in Canada 
(Poon et al., 1988). G6PD Viangchan carries a single nucleotide mutation at position 
871 from G to A. The mutation will substitute a Valine amino acid to Methionine at 
position 291 (Beutler et al., 1991).  
G6PD Viangchan belongs to WHO Class II which only produces 10 % of the 
total enzyme activity (severe G6PD deficiency). The same 871 G>A mutation was also 
found in G6PD Jammu which is originated from India (Beutler et al., 1991). The only 
difference between the two variants is nucleotide polymorphism at position 311, where 
it was C in G6PD Jammu and T in G6PD Viangchan. G6PD Viangchan was found to 
be the most common variant in Laotians (Iwai et al., 2001, Hsia et al., 1993), Malaysian 
Malays (Ainoon et al., 2003, Yusoff et al., 2004), Cambodians (Matsuoka et al., 2005, 
Louicharoen and Nuchprayoon, 2005) and Vietnamese (Matsuoka et al., 2007).  
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Figure 2.8: Non-oxidative and oxidative pathways of PPP and the paths involved in 
NADP and GSH production (Nelson et al., 2008). Image also shows the reduction 
of GSH upon the reduction if NAPD. G6PD gene pathway is very crucial in 
maintaining cellular redox. 
 
 
 
Figure 2.9: Oxygen species are generated by cellular processes such as 
respiration and redox enzymes. Oxygen species is converted to hydrogen peroxide 
and it detoxified through a metabolic pathway. Catalase and peroxidases then 
convert hydrogen peroxide to water (Nelson et al., 2008). 
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Figure 2.10:  Frequency of G6PD deficiency worldwide. The frequency is higher in countries with tropical weather. The highest frequency 
is found across African and South East Asian countries. (Cappellini and Fiorelli, 2008) 
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2.3.6 Clinical Presentation 
Acute haemolysis anaemia 
Patients with G6PD deficiency commonly appears are asymptomatic unless triggered 
with oxidants (drug or fava bean) (Figure 2.11) or infection (Hosnut et al., 2008). The 
most usual symptom in patients is haemolytic anaemia but normally periodic. They 
present with anaemia, increased red cell destruction or in alteration in blood 
morphology (Corash et al., 1980, Brewer et al., 1961) A paper from Dern 1954 shows 
that subjects (African origin) with G6PD A- shows acute haemolytic following the 
administration of primaquine at day 2 to 4 (Fernando et al., 2011). Figure 2.12 shows 
the appearance of RBC that undergoes haemolytic anaemia. 
Sudden onset of jaundice, pallor and dark urine, with or without abdominal and 
back pain was observed. A same pattern of haemolysis was witnessed among 
Caucasians and Asian (Bouma et al., 1995). Mediterranean B- variant, on the other 
hand, is vulnerable to life-threatening haemolysis when treated with primaquine 
(Beutler 1991). There are also chemical products that commonly causes haemolysis 
which includes naphthalene (moth balls) (Figure 2.13), aniline dyes, and henna 
compounds used for hair dyes and tattoo (Figure 2.14) (Raupp et al., 2001).  
Another common factor of haemolysis is an infection (Shannon and Buchanan, 
1982, Burka et al., 1966). Although the degree of haemolysis is usually mild, massive 
intravascular haemolysis can cause acute renal failure. Several infectious agents have 
been described including salmonella (Chan et al., 1971, Hersko and Vardy, 1967, 
Constantopoulos et al., 1973), E coli (Burka et al., 1966), beta-haemolytic streptococci 
(Mengel et al., 1967), rickettsia (Mengel et al., 1967) and viral hepatitis (Phillips and 
Silvers, 1969, Salen et al., 1966). 
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Neonatal jaundice/hyperbilirubinemia  
G6PD deficiency is one of the major risk factors for severe neonatal jaundice (Kaplan 
and Hammerman, 2009). Jaundice can be very severe in some G6PD-deficient babies, 
especially in association with prematurity, infection, and/or environmental factors 
(such as naphthalene-camphor balls used in babies' bedding and clothing). Figure 2.15 
shows deposition of bilirubin in the basal ganglia (yellow deposited) in kernicterus 
patient. G6PD related neonatal jaundice rarely present at birth but shows clinical onset 
is between day 2 and 3 (Kaplan and Hammerman, 2004). A huge study comprised a 
total of five cohorts with 21 585 participants in the year 2015 shows that 3.92 % of 
G6PD deficiency neonates have a relative risk of  hyperbilirubinemia (Liu et al., 2015). 
Another study from USA Kernicterus Registry from 1992 to 2004 revealed that 30% 
of the kernicterus cases are associated with G6PD deficiency (Johnson et al., 2009).  
Neonatal jaundice with G6PD deficiency can result in kernicterus or bilirubin 
encephalopathy and permanent neurologic damage (Weng and Chiu, 2010, Dhillon et 
al., 2003, Valaes, 1994) if not managed poorly. Figure 2.16 shows clinical presentation 
of babies with neonatal jaundice. 
Chronic non-spherocytic haemolytic anaemia (CNSHA) 
CNSHA is the most severe form of G6PD-deficiency (Costa et al., 2000). CNSHA 
classified under G6PD deficiency Class I which produced less than 10 % of normal 
G6PD enzyme production. As in 2000, 61 G6PD molecular variants associated with 
CNSHA have been identified but not all of them cause a severe reduction in the 
enzyme activity (Fiorelli et al., 2000). Many patients with CNSHA caused by G6PD 
deficiency have a history of severe neonatal jaundice, chronic anaemia often requiring 
a blood transfusion. Patients also present with lifelong chronic haemolytic anaemia 
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accompanied by episodes of acute crisis triggered by infections or the ingestion of 
certain drugs (Francis et al., 2013). 
2.3.7 Management 
Avoiding any of the triggers is a common management to avoid haemolysis in G6PD 
deficiency. In a very rare case, when anaemia is severe, a blood transfusion may be 
necessary. Supplements such as folic acid and iron might possibly useful in haemolysis 
too. Infants with prolonged neonatal jaundice which is caused by G6PD deficiency 
will receive phototherapy with bili light and perhaps an exchange of transfusion to 
prevent kernicterus. Haemolysis that is caused by infection, the cause of the infection 
is normally treated first. Antibody prescription will be carried out to cure the infection 
which will eventually subsidise the triggered haemolysis.  
Therefore, in this experiment, we would like to propose gene therapy based 
treatment to cure the deficiency. Gene therapy treatment has been widely used for 
many genetic diseases as well. Gene therapy treatment provides both transient and 
stable gene correction. Please refer the next chapter for a detailed explanation of gene 
therapy. 
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Figure 2.11: Fava bean consumption 
disrupts cellular function in G6PD 
deficient and causes AHA. 
Figure 2.12: Acute haemolysis in 
glucose-6-phosphate dehydrogenase 
(G6PD) deficiency (Bain, 2005). 
 
  
Figure 2.13: Mothball contains 
compound called naphthalene that can 
trigger hemolysis. 
Figure 2.14: Henna contains lawsone, a 
similar oxidative propert as mothball 
that can cause hemolysis in G6PD 
deficient patients. 
 
  
Figure 2.15: Postmortem specimens 
showing bilirubin deposition in the basal 
ganglia (yellow deposited) in kernicterus 
patient (Christensen et al., 2013). 
Figure 2.16: Clinical presentation of 
babies with neonatal jaundice. Baby’s 
skin and sclerae appear to be slightly 
yellow. 
 
